Skip to main content

Fiscal Wizard · Single-issue tearsheet

ZTS / Aug 13, 2026 Run #13794

ZTS

Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Composite verdict

A 88.9 / 100
Gated stand-aside 0 drivers · 8 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 1st of 2 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: volatile range

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $8.06Earnings power value $60.66Price $73.54

Priced above its no-growth earnings power value ($60.66/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Strong

88.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EBITDA Margin 100
Inventory Turnover 0
FCF Margin 100
Cash Conversion Cycle 0
Gross Margin 100
Revenue Growth (YoY) 9

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 44 signals shown.

Risk Gates

8 blocking 2 caution

8 guards active, 44 signals gated.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ZTS.